ALHC vs AZN

ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.